MX2018007266A - Combinaciones para el tratamiento del cancer. - Google Patents

Combinaciones para el tratamiento del cancer.

Info

Publication number
MX2018007266A
MX2018007266A MX2018007266A MX2018007266A MX2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A
Authority
MX
Mexico
Prior art keywords
combinations
cancer
treatment
agent
effective amount
Prior art date
Application number
MX2018007266A
Other languages
English (en)
Inventor
Wei Ge
Li Gang
D Hornby Zachary
Ee- Ren Lim Jonathan
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of MX2018007266A publication Critical patent/MX2018007266A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

En la presente se describen combinaciones que comprenden una cantidad terapéuticamente eficaz de un primer agente y una cantidad terapéuticamente eficaz de un segundo agente, en donde el primer agente es un inhibidor de la actividad de ALK, ROS1, TrkA, TrkB o TrkC, o una combinación de estos, y los métodos para utilizar tales combinaciones en el tratamiento de pacientes que tienen cáncer.
MX2018007266A 2015-12-18 2016-12-15 Combinaciones para el tratamiento del cancer. MX2018007266A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269805P 2015-12-18 2015-12-18
US201662428498P 2016-11-30 2016-11-30
PCT/US2016/066919 WO2017106492A1 (en) 2015-12-18 2016-12-15 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018007266A true MX2018007266A (es) 2018-11-09

Family

ID=59057572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007266A MX2018007266A (es) 2015-12-18 2016-12-15 Combinaciones para el tratamiento del cancer.

Country Status (11)

Country Link
US (2) US10869864B2 (es)
EP (1) EP3389645A4 (es)
JP (1) JP7061068B2 (es)
KR (1) KR20180096621A (es)
CN (1) CN108697661A (es)
AU (1) AU2016370846B2 (es)
BR (1) BR112018012255A2 (es)
CA (1) CA3008663A1 (es)
IL (1) IL259996A (es)
MX (1) MX2018007266A (es)
WO (1) WO2017106492A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US10085979B2 (en) 2014-12-02 2018-10-02 Ignyta, Inc. Combinations for the treatment of neuroblastoma
JP7061068B2 (ja) 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
EP3654952A1 (en) * 2017-07-19 2020-05-27 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3679932A1 (en) 2017-09-06 2020-07-15 ONO Pharmaceutical Co., Ltd. METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
EP3746436A4 (en) * 2018-08-16 2022-03-16 F. Hoffmann-La Roche AG CONDENSED CYCLIC COMPOUNDS
SG11202102485TA (en) * 2018-10-05 2021-04-29 Univ Illinois Combination therapy for the treatment of uveal melanoma
WO2021108672A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
US11524006B2 (en) * 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
AU2882699A (en) 1998-02-27 1999-09-15 Watson Pharmaceuticals, Inc. Stabilizing composition for pharmaceutical dosage forms
GEP20032922B (en) * 1999-01-13 2003-03-25 Warner Lambert Co Benzoheterocycles and Their Use as MEK Inhibitors
JP2002275068A (ja) 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
JP2005508337A (ja) 2001-09-27 2005-03-31 スミスクライン ビーチャム コーポレーション 化合物
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003251875A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
AU2003278249B8 (en) 2002-09-05 2010-11-18 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
MXPA05005554A (es) 2002-12-12 2005-07-26 Aventis Pharma Sa Derivados de aminoindazol y su utilizacion como inhibidores de quinasas.
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
AP2114A (en) 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1626950A4 (en) 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc SERTRALINZUSAMMENSETZUNGEN
EP1673085B1 (en) 2003-09-26 2011-11-09 Exelixis, Inc. C-met modulators and methods of use
ATE411395T1 (de) 2003-10-24 2008-10-15 Oncalis Ag Verfahren zur identifizierung und/oder validierung von rezeptortyrosinkinase-inhibitoren
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7605272B2 (en) 2005-01-27 2009-10-20 Kyowa Hakko Kirin Co., Ltd. IGF-1R inhibitor
WO2006111035A1 (en) 2005-04-21 2006-10-26 Oncalis Ag Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
US20080214521A1 (en) 2005-08-09 2008-09-04 Martin Schuler Sensitization of Drug-Resistant Lung Caners to Protein Kinase Inhibitors
JP2009520825A (ja) 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
BRPI0714359A2 (pt) 2006-07-07 2013-02-26 Bristol-Myers Squibb Company inibidores de pirrolotriazina cinase
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
KR101364277B1 (ko) 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
MX2009006170A (es) 2006-12-11 2009-06-19 Irmc Llc Compuestos y composiciones como inhibidores de cinasa.
DK2120932T3 (da) 2006-12-20 2014-10-13 Nerviano Medical Sciences Srl Indazolderivater som kinasehæmmere til behandling af kræft
WO2009009016A1 (en) * 2007-07-06 2009-01-15 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
EP2176231B1 (en) 2007-07-20 2016-10-19 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
ES2635131T3 (es) 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
TWI458729B (zh) 2008-10-22 2014-11-01 Array Biopharma Inc 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
CN102924479A (zh) 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
JP2015508644A (ja) 2012-02-08 2015-03-23 インサイト ジェネティクス インコーポレイテッド 癌の診断および治療のためのｒｏｓ１の融合体に関する方法および組成物
NZ627900A (en) 2012-03-06 2016-08-26 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
AU2013265288B2 (en) 2012-05-23 2017-12-21 Nerviano Medical Sciences S.R.L. Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
RU2015115634A (ru) 2012-09-28 2016-11-20 Онкоэтикс Гмбх Фармацевтический состав, содержащий соединения тиенотриазолодиазепина
WO2014093750A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
EP3082957B1 (en) * 2013-12-20 2022-04-06 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
NZ727418A (en) 2014-05-15 2023-03-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
CN106852119A (zh) 2014-06-13 2017-06-13 翁科埃斯克斯有限公司 利用噻吩并***并二氮杂*化合物治疗非小细胞肺癌和/或小细胞肺癌的方法
CN203954606U (zh) 2014-08-06 2014-11-26 朱红英 一种跳跳球
US10085979B2 (en) 2014-12-02 2018-10-02 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3227686A4 (en) 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
CA2987281A1 (en) 2015-05-29 2016-12-08 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
BR112017025773A2 (pt) * 2015-06-01 2018-08-14 Loxo Oncology Inc métodos de diagnóstico e tratamento de câncer
SG11201803438XA (en) * 2015-10-26 2018-05-30 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP7061068B2 (ja) 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
EP3654952A1 (en) 2017-07-19 2020-05-27 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形

Also Published As

Publication number Publication date
CN108697661A (zh) 2018-10-23
AU2016370846B2 (en) 2022-08-25
EP3389645A1 (en) 2018-10-24
US20190000840A1 (en) 2019-01-03
IL259996A (en) 2018-07-31
BR112018012255A2 (pt) 2018-12-04
JP7061068B2 (ja) 2022-04-27
JP2019502683A (ja) 2019-01-31
CA3008663A1 (en) 2017-06-22
US10869864B2 (en) 2020-12-22
WO2017106492A1 (en) 2017-06-22
KR20180096621A (ko) 2018-08-29
US20210113555A1 (en) 2021-04-22
EP3389645A4 (en) 2019-12-18
AU2016370846A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2017006230A2 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
GB2541571A (en) Pharmaceutical compositions
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2017002489A (es) Agentes terapeuticos humanos.
IN2014MU00303A (es)
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
BR112018002530A2 (pt) combinações e usos e tratamentos destas
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MX2017013047A (es) Tratamiento de dolor.
PH12021550122A1 (en) Solubilized apyrases, methods and use